|Bid||0.3011 x 45100|
|Ask||0.3150 x 1100|
|Day's Range||0.2986 - 0.3200|
|52 Week Range||0.2500 - 0.9400|
|Beta (5Y Monthly)||0.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 07, 2022 - Feb 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.08|
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 7.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Revenue Increased 12% Year-Over-YearRecord Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, Wash., May 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced its financial results for the third quarter of fiscal 2022 ended March 31, 2022. Revenue for the third quarter of fiscal 2022 grew 12% to $2.91 million versus $2.60 million in the prior year comparable period. The Company’s co
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -5.26% and 6.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?